OSTEOPOROSIS IS A CHRONIC, PROGRESSIVE CONDITION AND CONTINUED TREATMENT IS ESSENTIAL TO ENSURE LONG-TERM BENEFIT1
Use of a ‘treat-to-target’ strategy can help enhance and individualize the care of patients with chronic diseases including osteoporosis.
Total hip BMD T-scores >-2.5 are associated with a lower incidence of non-vertebral fractures in a study of Prolia®, supporting the concept that a specific T-score can be considered as a practical goal for therapy.2
Improvements in total hip BMD T-score and a sustained low incidence of non-vertebral fractures are observed throughout 10 years of Prolia® treatment.2,3
Graph has been adpated from Ferrari et. al 2016
to find out how long you should treat your patients with Prolia®
to achieve a certain increase in BMD.
BMD: bone mineral density; CI: confidence interval.
- Brown, et al. J Bone Miner Res. 2013;28:746–52.
- Ferrari S, et al. Osteoporos Int. 2016;27(Suppl 1): OC17.
- Bone HG, et al. Lancet Diabetes Endocrinol. 2017;5:513–23.